U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C35H58N5O6P
Molecular Weight 675.8387
Optical Activity ( + / - )
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ODE-BN-PMEG

SMILES

CCCCCCCCCCCCCCCCCCOCCOP(=O)(COCCN1C=NC2=C1N=C(N)NC2=O)OCC3=CC=CC=C3

InChI

InChIKey=AHSNBFKBLUUKAW-UHFFFAOYSA-N
InChI=1S/C35H58N5O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-24-43-26-27-45-47(42,46-28-31-21-18-17-19-22-31)30-44-25-23-40-29-37-32-33(40)38-35(36)39-34(32)41/h17-19,21-22,29H,2-16,20,23-28,30H2,1H3,(H3,36,38,39,41)

HIDE SMILES / InChI
Rabacfosadine was approved in 2017 under the brand name Tanovea-CA1 for the treatment of canine lymphoma. In addition, this drug has demonstrated effectiveness against non-Hodgkin's lymphoma in dogs, as well as canine cutaneous T-cell lymphoma, and relapsed canine B-cell lymphoma. Rabacfosadine a prodrug, which is hydrolyzed intracellularly to the metabolites, 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) and 9-(2-phosphonylmethoxyethyl) guanine (PMEG). PMEG is then converted to its active phosphorylated form, which is a chain-terminating inhibitor of the replicative deoxyribonucleic acid (DNA) polymerases.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.7 µM [EC50]
PubMed

PubMed

TitleDatePubMed
Tanovea® for the treatment of lymphoma in dogs.
2018 Aug
Patents

Patents

Sample Use Guides

Administer TANOVEA-CA1 at 1 mg/kg body weight as a 30-minute intravenous infusion, once every three weeks, for up to five doses. Stepwise dose reductions to 0.8 mg/kg and 0.66 mg/kg or dose delays may be used to manage adverse reactions.
Route of Administration: Intravenous
Name Type Language
ODE-BN-PMEG
Common Name English
PHOSPHONIC ACID, P-((2-(2-AMINO-1,6-DIHYDRO-6-OXO-9H-PURIN-9-YL)ETHOXY)METHYL)-, 2-(OCTADECYLOXY)ETHYL PHENYLMETHYL ESTER
Systematic Name English
Code System Code Type Description
FDA UNII
A1DXM66YHY
Created by admin on Sat Dec 16 13:53:41 GMT 2023 , Edited by admin on Sat Dec 16 13:53:41 GMT 2023
PRIMARY
PUBCHEM
135565845
Created by admin on Sat Dec 16 13:53:41 GMT 2023 , Edited by admin on Sat Dec 16 13:53:41 GMT 2023
PRIMARY
CAS
1626364-18-8
Created by admin on Sat Dec 16 13:53:41 GMT 2023 , Edited by admin on Sat Dec 16 13:53:41 GMT 2023
PRIMARY